Ehsan Fayazzadeh

Ehsan Fayazzadeh

Auto-generated profile, based on publicly available information

Ehsan Fayazzadeh

Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2019 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
NKNischal Koirala
Nischal Koirala
DDDola Das
Dola Das
EFEhsan Fayazzadeh
Ehsan Fayazzadeh
SSSanghamitra Sen
Sanghamitra Sen
AMAndrew McClain
Andrew McClain
GMGordon McLennan
Gordon McLennan

7 January 2008 in Anz Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SRShahram Rabbani
Shahram Rabbani
HAHossein Ahmadi
Hossein Ahmadi
EFEhsan Fayazzadeh
Ehsan Fayazzadeh
MSMohammad Sahebjam
Mohammad Sahebjam
MBMohammad A. Boroumand
Mohammad A. Boroumand
SNSeyed Mahdi Nassiri
Seyed Mahdi Nassiri

24 January 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
DDDola Das
Dola Das
EFEhsan Fayazzadeh
Ehsan Fayazzadeh
XLXin Li
Xin Li
NKNischal Koirala
Nischal Koirala
AWAkshay Wadera
Akshay Wadera
GMGordon McLennan
Gordon McLennan

1 August 2020 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
DBDavid T Broome
David T Broome
GGGauri B Gadre
Gauri B Gadre
EFEhsan Fayazzadeh
Ehsan Fayazzadeh
JBJames Bena
James Bena
CNChristian Nasr
Christian Nasr
Objective:: To identify novel prognostic risk factors and compare them with other known prognostic risk factors in follicular-cell-derived thyroid carcinoma (FDTC) with distant metastases. Methods:: A retrospective review was conducted of adult patients with metastatic FDTC seen at a tertiary care center between January 1990 and December 2010. A 15-year Kaplan–Meier survival estimate was created for overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HR) and P values from Cox proportional hazard models were used with a 95% CI. Results:: There were 143 patients (60.1% male, 39.9% female), of whom 104 (72.7%) patients had papillary, 30 (21.0%) had follicular, 5 (3.5%) had poorly differentiated, and 4 (2.8%) had Hürthle cell cancers. Median length of follow-up was 80.0 months (range 1.0–564.0). The 15-year mortality rate was 32.2% and cancer-specific mortality was 25.2%, with OS and CSS having the same risk factors. Lung was the most common site of metastases in 53 patients (37.1%), and patients with pleural effusions had significantly lower CSS (HR = 5.21, CI = 1.79–15.12). Additional risk factors for a decreased CSS included: older age upon diagnosis (>45 years, HR = 4.15, CI = 1.43–12.02), multiple metastatic locations (HR = 3.75, CI = 1.32–10.67), and incomplete/unknown tumor resection (HR = 2.35, CI = 1.18–4.67). Conclusion:: This study is the first to demonstrate that pleural effusion is a poor prognostic sign in patients with FDTC with distant metastases and compare this risk with other accepted prognostic variables.

1 January 2014
Verified
Journal Article
Closed access
EFEhsan Fayazzadeh
Ehsan Fayazzadeh
SRSina Rahimpour
Sina Rahimpour
SASeyed Mohsen Ahmadi
Seyed Mohsen Ahmadi
SFShahrokh Farzampour
Shahrokh Farzampour
MAMaryam Sotoudeh Anvari
Maryam Sotoudeh Anvari
MBMohammad Ali Boroumand
Mohammad Ali Boroumand

1 September 2016
Verified
Journal Article
Open access
EFEhsan Fayazzadeh
Ehsan Fayazzadeh
HYHana Yavarifar
Hana Yavarifar
SRSeyyed Reza Rafie
Seyyed Reza Rafie
SMSadrollah Motamed
Sadrollah Motamed
MAMaryam Sotoudeh Anvari
Maryam Sotoudeh Anvari
MBMohammad Ali Boroumand
Mohammad Ali Boroumand
One of the main challenges in skin flap surgery is tissue ischemia and following necrosis. The present study compares the effects of fibroblast growth factors 1 and 2 on increasing cutaneous vasculature, improving ischemia, and preventing distal necrosis in ischemic skin flaps in rat model. Thirty rats were allocated into 3 groups (n=10) and 2×8 cm dorsal random-pattern skin flaps were raised after four daily subdermal injections of normal saline (control group), fibroblast growth factor 1 (FGF-1 group; 2.5 µg/day), or fibroblast growth factor 2 (FGF-2 group; 2.5 µg/day) at designated flap areas. Skin flap viability and number of blood vessels were evaluated on day 10 after elevation by planimetric analysis and histological examination. It was shown that administrations of FGF-1 and FGF-2 significantly decreased the percentage of flap necrosis and improved the percentage of ischemic survivable area, compared to the control samples. Meanwhile, the differences between these factors in terms of preventing skin flap necrosis and improving ischemia were also significant. The number of visible blood vessel sections was also higher in FGF-1 and FGF-2 groups than in the control group. These findings suggest that, while FGF-2 is still much more potent than FGF-1, treatment with either of these drugs could be very effective in increasing the survival of surgical flaps at risk (length to width ratio>3) in situations that other therapeutic options could not be considered.